Jaktinib 5 Tablet contains Tofacitinib 5 mg, a Janus kinase (JAK) inhibitor used primarily in the treatment of autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib works by selectively inhibiting JAK enzymes, which play a critical role in the signaling pathways involved in the inflammatory and immune responses. By modulating these pathways, Jaktinib 5 helps reduce inflammation, joint damage, and other symptoms associated with autoimmune disorders. This medication is indicated for adult patients who have had an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (DMARDs). Jaktinib 5 is administered orally, typically twice daily, with or without food, as directed by a healthcare professional. Patients should be monitored regularly for potential adverse effects, including infections, changes in blood counts, liver enzyme elevations, and lipid abnormalities. Caution is advised in patients with a history of chronic infections, malignancies, or hepatic impairment. It is contraindicated in patients with active serious infections. Prior to initiating therapy, screening for tuberculosis and viral hepatitis is recommended. Jaktinib 5 should be used under strict medical supervision, with periodic laboratory assessments to ensure safety and efficacy.